ANI Pharmaceuticals
ANIP • NASDAQ
ANI Pharmaceuticals is a drug manufacturers - specialty & generic company in the healthcare sector trading on NASDAQ, led by CEO Nikhil Lalwani, with a market cap of $1.6B.
CEONikhil Lalwani
Market Cap$1.6B
Drug Manufacturers - Specialty & Generic
Healthcare
Employees642.0
Websiteanipharmaceuticals.com
Next Earnings
Upcoming earnings announcement for ANI Pharmaceuticals
Date
Friday, May 8, 2026 (in a month)
Timing
Before Market Open (6:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
$1.30
Revenue Estimate
$212.7M
Earnings History
Past 12 earnings reports for ANI Pharmaceuticals
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 27, 2026 | Q4 2025 | $2.33Est: $1.83 | +27.3% | $247.1MEst: $231.8M | +6.6% |  10-K |
| Nov 7, 2025 | Q3 2025 | $2.04Est: $1.61 | +26.7% | $227.8MEst: $212.2M | +7.3% | 10-Q |
| Aug 8, 2025 | Q2 2025 | $1.80Est: $1.26 | +42.9% | $211.4MEst: $189.4M | +11.6% | 10-Q |
| May 9, 2025 | Q1 2025 | $1.70Est: -$0.06 | +2933.3% | $197.1MEst: $180.7M | +9.1% | 10-Q |
| Feb 28, 2025 | Q4 2024 | $1.63Est: $0.29 | +462.1% | $190.6MEst: $175.4M | +8.7% | 10-K |
| Nov 8, 2024 | Q3 2024 | $1.34Est: $1.09 | +22.9% | $148.3MEst: $144.4M | +2.8% | 10-Q |
| Aug 6, 2024 | Q2 2024 | $1.02Est: $0.94 | +8.5% | $138.0MEst: $128.6M | +7.3% | 10-Q |
| May 10, 2024 | Q1 2024 | $1.21Est: $0.99 | +22.2% | $137.4MEst: $125.5M | +9.5% | 10-Q |
| Feb 29, 2024 | Q4 2023 | $1.00Est: $0.85 | +17.6% | $131.7MEst: $122.2M | +7.7% | 10-K |
| Nov 8, 2023 | Q3 2023 | $1.27Est: $0.84 | +51.2% | $131.8MEst: $111.9M | +17.8% | — |
| Aug 9, 2023 | Q2 2023 | $1.28Est: $0.68 | +88.2% | $116.5MEst: $98.7M | +18.1% | 10-Q |
| May 8, 2023 | Q1 2023 | $1.17Est: $0.35 | +234.3% | $106.8MEst: $83.5M | +27.9% | — |